Thomas LeBlanc

Overview:

I am a medical oncologist, palliative care physician, and patient experience researcher, and serve as Chief Patient Experience and Safety Officer for the Duke Cancer Institute. My clinical practice focuses on the care of patients with hematologic malignancies, with a particular emphasis on myeloid conditions and acute leukemias including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs / MPDs, CML).  

As founding Director of the Duke Cancer Patient Experience Research Program (CPEP), my research investigates common issues faced by people with cancer, including issues of symptom burden, quality of life, psychological distress, prognostic understanding, and treatment decision-making. This work aims to improve patients' experiences living with serious illnesses like blood cancers, including the integration of specialist palliative care services to provide an extra layer of support along with their comprehensive cancer care. More broadly, our team in CPEP conducts various studies of patient experience and outcomes issues in oncology, including retrospective chart review studies, comparative effectiveness work, prospective observational studies and registries, and qualitative research, along with efforts to facilitate the integration of patient-generated health data (PGHD) into routine cancer care processes, such as with electronic patient-reported outcome measures (ePROs) and other mobile health interventions (mHealth). 

This work has led to recognition as an "Inspirational Leader under 40" by the American Academy of Hospice and Palliative Medicine (AAHPM), "Fellow" status from the Academy in 2016, the 2018 international "Clinical Impact Award" from the European Association for Palliative Care, and the AAHPM "Early Career Investigator" award in 2020. I served as 2017-18 Chair of the ASCO Ethics Committee, and currently Chair the Scientific Review Committee of the NIH/NINR-funded Palliative Care Research Cooperative Group (PCRC; www.palliativecareresearch.org). I have served on various national guideline panels for AML and for palliative/supportive care issues in oncology, and was inducted as a Fellow of the American Society of Clinical Oncology (FASCO) in 2021. To date I have published over 200 Medline-indexed articles, and several chapters in prominent textbooks of oncology and palliative medicine.

Positions:

Associate Professor of Medicine

Medicine, Hematologic Malignancies and Cellular Therapy
School of Medicine

Associate Professor in Population Health Sciences

Population Health Sciences
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2006

Duke University

Intern

Duke University School of Medicine

Resident

Duke University School of Medicine

Chief Medical Resident

Duke University School of Medicine

Fellowship, Hospice And Palliative Medicine

Duke University School of Medicine

Fellow, Medical Oncology

Duke University School of Medicine

Grants:

AC220-A-U302 trial

Administered By
Duke Clinical Research Institute
Awarded By
Daiichi Sankyo Inc
Role
Principal Investigator
Start Date
End Date

Prognostic understanding and decision-making in acute myeloid leukemia (AML)

Administered By
Duke Cancer Institute
Awarded By
American Cancer Society, Inc.
Role
Principal Investigator
Start Date
End Date

Randomized Trial of Inpatient Palliative Care for Patients with Hematologic Malignancies

Administered By
Duke Cancer Institute
Awarded By
Massachusetts General Hospital
Role
Principal Investigator
Start Date
End Date

Understanding Barriers to Oral Therapy Adherence in Adult/Older-Adult AML Patients (429 Oral)

Administered By
Duke Cancer Institute
Awarded By
Carevive Systems, Inc.
Role
Principal Investigator
Start Date
End Date

Palliative care and shared decision-making for patients with blood cancers

Administered By
Duke Cancer Institute
Awarded By
Cambia Health Foundation
Role
Principal Investigator
Start Date
End Date

Publications:

An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia After Experiencing Pleural Effusion During Dasatinib Therapy.

INTRODUCTION: Treatment with dasatinib for chronic myeloid leukemia (CML) has been associated with development of pleural effusion, however data regarding its optimal management are limited. We examined treatment patterns and healthcare resource utilization (HCRU) and costs among patients with CML treated with dasatinib who experienced a subsequent pleural effusion. METHODS: Adults with CML and ≥1 pharmacy claim for dasatinib in 2015-2018 who experienced pleural effusion after dasatinib were identified using data from claims databases. RESULTS: Overall, 123 patients were eligible. After 1 year, of the 38.2% of patients with a dose modification, 72.3% did not switch treatment; amongst these patients, 70.6% continued treatment. Among patients with a stable dose after pleural effusion (61.8%), 57.9% later switched to another TKI. The mean (SD) duration of dasatinib treatment after pleural effusion was 262.0 (124.0) days for patients with a dose modification versus 149.1 (155.2) days for those with a stable dose (p < 0.001). HCRU and costs were similar between groups. DISCUSSION/CONCLUSION: Dasatinib dose modification after pleural effusion was not always required; however, patients with dose modifications continued therapy for a longer duration with a lower rate of switching to another TKI versus patients who remained on a stable dose.
Authors
McBride, A; Brokars, J; Reddy, SR; Chang, E; Tarbox, MH; LeBlanc, TW
MLA Citation
URI
https://scholars.duke.edu/individual/pub1571367
PMID
37037194
Source
pubmed
Published In
Acta Haematol
Published Date
DOI
10.1159/000530512

In Their Own Words: A Qualitative Study of Coping Mechanisms Employed By Patients with Acute Myeloid Leukemia

Authors
Daniels, N; Bodd, M; Locke, SC; Leblanc, TW
MLA Citation
Daniels, Nikki, et al. “In Their Own Words: A Qualitative Study of Coping Mechanisms Employed By Patients with Acute Myeloid Leukemia.” Blood, vol. 140, no. Supplement 1, American Society of Hematology, 2022, pp. 13267–68. Crossref, doi:10.1182/blood-2022-165372.
URI
https://scholars.duke.edu/individual/pub1568850
Source
crossref
Published In
Blood
Volume
140
Published Date
Start Page
13267
End Page
13268
DOI
10.1182/blood-2022-165372

The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World

Authors
Suvannasankha, A; LeBlanc, TW; Correll, JR; Carmichael, C; Gorsh, B; Martin, M; Kitchen, H; Eliason, L; Thursfield, M; Boytsov, N; Brown Hajdukova, E; Lewis, MB; Mackay, C; Paka, P; O'Neill, A; Perera, S; Naine, S; Molinari, A; Hanna, M; Kleinman, D
MLA Citation
Suvannasankha, Attaya, et al. “The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World.” Blood, vol. 140, no. Supplement 1, American Society of Hematology, 2022, pp. 13264–66. Crossref, doi:10.1182/blood-2022-159637.
URI
https://scholars.duke.edu/individual/pub1568851
Source
crossref
Published In
Blood
Volume
140
Published Date
Start Page
13264
End Page
13266
DOI
10.1182/blood-2022-159637

What Do Patients Think about Palliative Care? A National Survey of Hematopoietic Stem Cell Transplant Recipients.

Palliative care (PC) benefits patients undergoing hematopoietic stem cell transplantation (HSCT) but remains under-utilized. Whereas transplant physicians report concerns regarding how patients perceive PC, HSCT recipients' perceptions about PC remain unaddressed. We conducted a multi-site cross-sectional survey of autologous and allogeneic HSCT recipients 3-12 months post-transplant to assess their familiarity, knowledge, and perception of PC, as well as their unmet PC needs. We computed a composite score of patients' perceptions of PC and used a generalized linear regression model to examine factors associated with these perceptions. We enrolled 69.6% (250/359) of potential participants (Median age = 58.1; 63.1% autologous HSCT). Overall, 44.3.8% (109/249) reported limited knowledge about PC and 52% (127/245) endorsed familiarity with PC. Most patients felt hopeful (54%) and reassured (50%) when they heard the term PC; 83% saw referral as a sign their doctor cared about what was happening to them. In multivariate analyses, patients who were more knowledgeable about PC were more likely to have positive perceptions of PC (B = 7.54, SE=1.61, P < 0.001). Patients' demographics, HSCT features, quality of life, and symptom burden were not significantly associated with perceptions of PC. HSCT recipients have positive perceptions of PC, though many have limited knowledge about its role. Patients who were more knowledgeable about PC were more likely to have positive perceptions of PC. These data do not support transplant physicians' negative concerns about how patients perceive PC and underscore the need to further educate patients and transplant physicians about PC.
Authors
Barata, A; Abrams, HR; Meyer, CL; Mau, L-W; Mattila, D; Burns, LJ; Ullrich, CK; Murthy, HS; Wood, WA; Petersdorf, EW; LeBlanc, TW; El-Jawahri, A
MLA Citation
Barata, Anna, et al. “What Do Patients Think about Palliative Care? A National Survey of Hematopoietic Stem Cell Transplant Recipients.Blood Adv, Mar. 2023. Pubmed, doi:10.1182/bloodadvances.2023009712.
URI
https://scholars.duke.edu/individual/pub1568854
PMID
36877661
Source
pubmed
Published In
Blood Adv
Published Date
DOI
10.1182/bloodadvances.2023009712

Removing Transfusion Dependence As a Barrier to Hospice Enrollment (BRUOG-407)

Authors
Egan, PC; Pelcovits, A; Leblanc, TW; Krar, C; Donnelly, S; Rubin, L; Olszewski, A; Reagan, JL; Niroula, R
MLA Citation
Egan, Pamela C., et al. “Removing Transfusion Dependence As a Barrier to Hospice Enrollment (BRUOG-407).” Blood, vol. 140, no. Supplement 1, American Society of Hematology, 2022, pp. 7946–47. Crossref, doi:10.1182/blood-2022-156951.
URI
https://scholars.duke.edu/individual/pub1568852
Source
crossref
Published In
Blood
Volume
140
Published Date
Start Page
7946
End Page
7947
DOI
10.1182/blood-2022-156951

Research Areas:

Aged
Attitude of Health Personnel
Attitude to Death
Attitude to Health
Cardiovascular Diseases
Clinical Competence
Clinical Trials as Topic
Cognition Disorders
Communication
Comparative Effectiveness Research
Decision Making
Diffusion of Innovation
Dyspnea
Ethics
Evidence-Based Medicine
Guideline Adherence
Health Services Research
Hematologic Neoplasms
Hospice Care
Information Dissemination
Inpatients
Jargon
Leukemia
Lung Neoplasms
Lymphoma
Medical education
Myelodysplastic Syndromes
Myeloproliferative Disorders
Neoplasms
Nonverbal Communication
Odds Ratio
Oncology Service, Hospital
Outcome Assessment (Health Care)
Oxygen
Pain
Pain Management
Palliative Care
Patient Selection
Patient-Centered Care
Perception
Prognosis
Quality of Health Care
Statistics as Topic
Terminal Care
Treatment Outcome
Withholding Treatment